BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure |
Attached as Exhibit 99.1 to this Current Report is the form of
presentation that BioLife Solutions, Inc. (the Company) expects
to use during future presentations of the Company.
The Company claims the protection of the safe harbor for
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that are not historical facts. Such
forward-looking statements, based upon the current beliefs and
expectations of management of the Company regarding, among other
things, the business of the Company, are subject to risks and
uncertainties, which could cause actual results to differ from
the forward-looking statements. The following factors and risks,
among others, could cause actual results to differ from those set
forth in the forward-looking statements: business conditions in
the U.S. and abroad; changing interpretations of generally
accepted accounting principles; requirements or changes adversely
affecting the business in which the Company is engaged;
management of rapid growth; intensity of competition; the
Companys ability to raise necessary funds; as well as other
relevant risks detailed in the Companys filings with the
Securities and Exchange Commission. The information set forth
herein should be read in light of such risks. The Company assumes
no obligation to update the information contained in this report.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| 99.1 | Corporate Presentation, dated February 15, 2017 |
About BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS)
BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service. BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS) Recent Trading Information
BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS) closed its last trading session down -0.02 at 2.02 with 51,132 shares trading hands.
